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ABSTRACT
Introduction. Animal studies and rare human studies have suggest-
ed a negative effect of barbiturates on cardiac function. Although 
intravenous (IV) phenobarbital is used routinely in children in the 
clinical setting, studies in children are lacking. We performed a study 
to evaluate effect of IV phenobarbital loading on myocardial systolic 
function of children.
Methods.xIn a prospective pilot study in children without congenital 
heart defects, the effect of IV phenobarbital was evaluated on the 
left ventricular systolic function measured by ejection fraction (EF) 
by Simpson’s method via an echocardiogram. Any child less than 18 
years of age who received IV loading dose of at least 20 mg/kg of 
phenobarbital given as an infusion over 20 - 30 minutes for various 
medical indications was eligible to take part in the study. Three mea-
surements of EF by an echocardiogram were made: before loading 
dose, 30 minutes after completion of the loading dose, and prior to 
the first maintenance dose. Relevant clinical data were recorded, 
including vital signs, immediately prior to each echocardiogram. 
Change of function as measured by EF over time was analyzed using 
linear mixed modeling methods. For this study, significant change in 
blood pressure was defined as a drop of at least 20 mmHg in systolic 
blood pressure.
Results. Ten children (70% female, age range two days to 8.2 years) 
were enrolled. Three had hypotension with a drop of systolic blood 
pressure greater than 20 mmHg from baseline. On examining the 
trajectory of EF on each individual graphically, the left ventricular 
EF tended to fall immediately following phenobarbital therapy and 
return to baseline on re-evaluation. These trajectories were statisti-
cally significant for EF. 
Conclusions. Phenobarbital had a direct and transient depressant 
effect on systolic function of the myocardium in one third of the cases. 
The depression in EF appeared to be transient with return to baseline 
in less than 24 hours. We recommend close monitoring with anticipa-
tion of decreased function in children when using IV phenobarbital. 
Kans J Med 2019;12(2):40-44.
INTRODUCTION
Since the synthesis of phenobarbital in 1912, it remains the most 
widely prescribed antiepileptic drug worldwide despite the develop-
ment of newer antiepileptic drugs.1 Phenobarbital is used widely in 
pediatric population for seizures, especially neonatal seizures. It also 
is used for seizure prevention in traumatic brain injury,2 neonatal 
opiate withdrawal,3 and resistant neonatal jaundice.4, 5 Phenobarbital 
is derived from barbiturate and used as a hypnotic and sedative that 
can be administered via intravenous (IV), intramuscular (IM), and 
oral routes. Phenobarbital is absorbed almost completely via oral and 
IM route but duration of peak effect varies. It takes anywhere from 
one to six hours for peak effect of phenobarbital to occur after oral/
IM administration. It takes only 30 minutes for peak effect to occur 
after IV phenobarbital administration. The clinical effect lasts for 
six to 10 hours after oral administration and four to 10 hours with IV 
administration of phenobarbital.6
Animal studies and rare human studies have suggested a negative 
effect of IV barbiturates on cardiac myocardial function.7-11 Barbi-
turates have been associated with depression of the myocardial, 
respiratory, and nervous system. Hypotension after IV phenobarbi-
tal administration in adults has been described in pharmacology and 
epilepsy literature.1 
Overall, it is important to investigate the underlying mechanism 
of a well-known adverse reaction of a commonly-used medication 
in children. However, there are very few studies reported in the lit-
erature assessing myocardial depressant effect of IV barbiturate 
administration in humans, especially in children.12,13 A prospective 
pilot study was performed to evaluate the effect of IV phenobarbital 
on cardiac myocardial function in children by a transthoracic echo-
cardiogram while monitoring the serum levels of phenobarbital.
METHODS
The study was approved by the institutional Committee for the 
Protection of Human Subjects (HSC-MS-12-0568) at the McGov-
ern Medical School at the University of Texas Health Science Center 
and Children’s Memorial Hermann Hospital, Texas Medical Center, 
Houston.   All parents gave informed written consent for participa-
tion. 
This prospective, single-center, pilot study was performed at 
the Pediatric Intensive Care Unit (PICU) at Children’s Memorial 
Hermann Hospital between 2013 and 2014. Any child, age 0 - 19 
years, who received IV loading dose of at least 20 mg/kg of pheno-
barbital in the PICU was eligible to take part in the study. Patient 
families were approached for the study only when the clinical condi-
tion required the use of IV phenobarbital and allowed enough time 
to enroll the child for the study and perform echocardiogram prior 
to administration of phenobarbital. Each child was used as their own 
control. Exclusion criteria included: (a) oral or intramuscular route 
used for phenobarbital loading dose and (b) any preexisting congeni-
tal heart defect.
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as IV infusion over 20 - 30 minutes for various medical indications 
as determined by the intensivist. An echocardiogram per protocol 
was performed before and after the loading dose. For the study, the 
vital signs were recorded immediately prior to each echocardiogram. 
According to the protocol, multiple cycled blood pressures were 
obtained every 15 minutes for one hour, every 30 minutes for one 
hour, then every 60 minutes via oscillometric technique using appro-
priate cuffs in all critical patients in the PICU. The clinical data were 
extracted from the medical records once the child was enrolled for 
the study. The echocardiograms were performed by a senior pediat-
ric cardiology fellow in a majority of the cases. The echocardiogram 
parameters were measured before and after the administration of IV 
phenobarbital and the measurements were evaluated and reported 
by a single cardiologist in an unblinded fashion. Since the children 
could be hypertensive or hypotensive at various time points, a sig-
nificant change in blood pressure was defined as a drop of at least 
20 mmHg in systolic blood pressure (SBP).  Phenobarbital serum 
levels also were recorded the after the loading dose to establish level 
related effect and the therapeutic levels were considered between 
15 - 40 mcg/ml. 
Transthoracic echocardiograms were performed prospectively 
on each patient. All echocardiograms were performed by a qualified 
pediatric cardiac sonographer or a senior pediatric cardiology fellow 
per protocol. The first echocardiogram was performed immediate-
ly prior to administration of phenobarbital loading dose. A second 
echocardiogram was performed 30 minutes after completion of the 
loading dose of phenobarbital and a third echocardiogram was per-
formed prior to the first maintenance dose of phenobarbital usually 
starting 12 - 24 hours after loading dose. 
On the first echocardiogram, screening was performed to rule out 
any major structural heart defect using a standard pediatric echocar-
diography protocol,14,15 including two-dimensional (2D), M-Mode, 
and Doppler measurements. All were interpreted by a board certi-
fied pediatric cardiologist in a blinded manner. All measurements 
were performed using commercially available single software 
(AGFA Heartlab Cardiovascular; AGFA Healthcare, Greensville, 
SC, USA). The left ventricular (LV) dimensions were measured 
from the M-mode echocardiogram obtained at the level of papillary 
muscle in parasternal short- and long-axis views. The left ventricular 
end-diastolic dimension (LVEDD) was measured at the end of dias-
tole (beginning of QRS-complex). The left ventricular end-systolic 
dimension (LVESD) was measured at the closest point of apposition 
between the septum and inferolateral wall. The shortening fraction 
(SFM) and ejection fraction (EFM) using the M-Mode data were 
calculated as markers to quantify systolic cardiac function.14,15 The 
ejection fraction (EFS) using the biplane Simpson’s formula from 
2D evaluations of the left ventricular volumes were calculated in the 
standard manner.14,15 
To examine the pattern/trajectory of the change in the left ven-
tricular systolic function parameters (SFM, EFM, EFS) over time, 
graphical and statistical methods were used. The changes over the 
three time periods for each patient were assessed. Based on the visu-
alized trajectories, linear mixed models were fit to the data. These 
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models enabled the modelling of both fixed and random effects and 
took into account the correlation between the repeated measures. A 
simple univariate model was fit with the left ventricular systolic func-
tion parameters as the outcome and time as the covariate. A random 
effect for each individual was fit. First, a model assuming a linear 
slope was fit. Subsequently, a model assuming a quadratic curve was 
fit. The model that best fit the data was assessed by log-likelihood 
ratio statistics. A p-value of 0.05 was set to indicate statistical sig-
nificance.
RESULTS
During the study period, 10 participants were recruited for this 
pilot study, where each child served as their own control (Table 1). 
Mean age of patients in months was 21.8 (± 38.5), age range was from 
two days to 8.2 years, 70% were females, five (50%) were African 
Americans, two (20%) were Caucasians, and three (30%) were 
Hispanics. During the screening echocardiogram, no patients had 
significant congenital heart disease and none had a history of a pre-
existing cardiovascular disease. 
The medical indications for use of IV phenobarbital were seizure 
prevention in traumatic brain injury (n = 5) and seizures (n = 5). 
Three children had both head trauma and seizures. One child was 
diagnosed with meningitis and none of the children were diagnosed 
with sepsis during the study. Figure 1 demonstrates the change in 
SBP, heart rates, and EF measures in all 10 children administered IV 
phenobarbital over time. Eight children were receiving respiratory 
support using a ventilator during the study duration prior to the first 
dose of phenobarbital. One child was on high flow nasal cannula and 
another was on room air with saturations via pulse oximetry above 
95%. None of the children were on any vasoactive or inotropic medi-
cations prior to the first echocardiogram except one child who was 
on IV dopamine infusion at the same dose during the first and second 
echocardiograms and a lower dose during the third echocardiogram. 
Of the 10 children, seven had a serum phenobarbital level obtained 
after the infusion and were in the therapeutic range or higher (Table 
1). No child developed significant bradycardia or a rash during the 
study.
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Table 1. Clinical characteristics of the study population. 
Age 
(months) Gender
Weight
(kg) BSA Race Indication
Phenobarbital 
Level
(mcg/ml)
1 90.25 F 36.8 1.09 Hispanic Seizure 16.6
2 3.22 F 5.57 0.29 African American Seizure 28.7
3 2.92 M 5.8 0.29 Caucasian Seizure, cardiac arrest 23.1
4 0.06 F 6.52 0.26 Caucasian Seizure, head trauma
5 9.72 F 8.9 0.38 Hispanic Head trauma
6 1.11 F 3.8 0.21 African American
Meningitis, 
seizure 42.1
7 7.98 M 10.3 0.42 African American
Seizure, head 
trauma
8 1.37 F 4.7 0.25 Hispanic Seizure, head trauma 57.8
9 2.96 M 3.8 0.23 African American
Head trauma, 
cardiac arrest 17.9
10 98.8 F 17.2 0.71 African American Seizure 42.6
Kg, kilogram; mcg/ml, micrograms per milliliters
    
Figure 1. Trajectory of the change in the systolic blood pressure in mmHg (SBP), heart rate in beats per minute (HR), and left ventricular ejection fraction percent 
by M-mode (EFM) and by Simpson’s method (EFS) over time in each child.
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sures in children administered phenobarbital. On examining the 
trajectory of each individual (Figure 1), the left ventricular systolic 
function parameters tended to fall in the first 12 hours following phe-
nobarbital therapy. Subsequently, the levels of parameters tended 
to rise, in most circumstances reaching the baseline levels after 24 
hours. As seen in Figure 1, the heart rate and blood pressure response 
were variable for each child and did not fit any pattern. Given these 
trajectories, we compared the fit of both the linear and quadratic 
models. As shown in Figure 1, the quadratic model appeared to fit 
the data well. Analysis using the mixed models technique (Table 2) 
showed that for all the three parameters, the levels appeared to fall 
just subsequent to therapy (negative coefficient for time) and rise 
thereafter (positive coefficient for time square). These trajectories 
were statistically significant for EFS.
Table 2. Evolution of left ventricular systolic function in patients 
administered phenobarbital. 
Echocardiogram 
measure β coefficient
+ 95% CI p-value
SFM
Time -6.5 -14.2 - 1.24 0.10
Time x Time 1.8 -0.12 - 3.71 0.065
EFM
Time -9.9 -20.7 - 0.83 0.07
Time x Time 2.65 -0.01 - 5.32 0.051
EFS
Time -14.7 -28.4 - -1.03 0.03*
Time x Time 3.4 0.03 - 6.82 0.048*
+Findings of mixed model linear regression analysis.
*p-value < 0.05.
SFM, shortening fraction by M-mode; EFM, ejection fraction by M-mode; 
EFS, ejection fraction by Simpson’s biplane. 
There was significant drop in SBP in three of the 10 children along 
with a significant drop in systolic left ventricular function between 
first and second echocardiograms that were done before and after IV 
phenobarbital of 20 mg/kg respectively. None of these three children 
were on any vasoactive or inotropic medications between first and 
second echocardiograms. The first child with seizures, on a ventila-
tor, had 21 mmHg drop in SBP with a 14-point decrease in EFM after 
phenobarbital loading dose with a serum phenobarbital level of 16.6 
mcg/ml. The second child with seizures, on a ventilator, had a 22 
mmHg drop in SBP with a 10-point decrease in EFM after pheno-
barbital loading dose with a serum phenobarbital level of 42.1 mcg/
ml. The third child with seizures, on room air, had a 24 mmHg drop in 
SBP after phenobarbital loading dose with a 7-point decrease in EFM 
with a serum phenobarbital level of 42.6 mcg/ml. The left ventricular 
systolic function improved to near that of the baseline for all three 
children at the time of third echocardiogram.  Overall, there was no 
significant correlation between the serum phenobarbital levels and 
hypotension.
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DISCUSSION
Although IV phenobarbital is used routinely in children in the clin-
ical setting, hemodynamic studies with its use in children are lacking. 
Our pilot study analyzed clinical and left ventricular myocardial 
contractility data with ejection fraction (EF) measured by an echo-
cardiogram via Simpson’s method obtained from children before and 
after IV phenobarbital with a loading dose of at least 20 mg/kg. The 
findings suggested a transient direct myocardial depressant effect of 
phenobarbital that occurs 30 minutes after completion of the loading 
dose but recovers prior to beginning of the maintenance dose.  
Previous animal studies suggested negative effect on left ventricu-
lar function with use of barbiturates.7-9 These animal studies have 
shown direct depression of myocardial function with barbiturates as 
noted by decrease in EF8 and cardiac function9 with pentobarbital. 
Manders et al.7 studied the effect of pentobarbital IV in 30 conscious 
dogs instrumented for measurement of hemodynamics, including 
cardiac output and regional blood flow distribution, left ventricular 
diameter, left ventricular pressure, and dP/dt and dD/DT (velocity 
of myocardial fiber shortening). Pentobarbital affected systemic and 
regional hemodynamics only slightly, but depressed the myocardium 
markedly. They concluded that induced tachycardia was not due to 
only vagolytic effect as previously thought, but is mediated predomi-
nantly through the arterial baroreceptor reflex.
Two previous studies in children have reported no significant 
change in EF with rectal barbiturate, methohexital. A study in chil-
dren using rectal 10% methohexital at 30 mg/kg found that the left 
ventricular EF, blood pressure, and cardiac index remained in the 
normal range, but there was a significant increase in heart rate and 
decrease in stroke volumes.12 Another study in children using rectal 
2% methohexital 25 mg/kg found a significant increase in heart rate, 
but unchanged blood pressure, cardiac index, stroke volume, and 
left ventricular EF.13 Both studies concluded that rectal methohexi-
tal could be used safely in healthy pediatric patients with minimal 
hemodynamic effect.
A known side effect of phenobarbital in adults is hypotension 
or a decrease in systolic blood pressures which was seen in 30% of 
our children. Since a previous study of IV phenobarbital use is not 
available in children, the findings from our study suggested that a 
clinician treating children should be prepared for a transient hypo-
tension with IV phenobarbital in one third of the cases and also to use 
the medication with caution in those with preexisting depressed left 
ventricular function. In our study, three children who received an IV 
bolus of phenobarbital for indication of seizures showed evidence of 
a significant drop in systolic blood by 20 mmHg or greater after IV 
phenobarbital load. The same three patients also showed significant 
myocardial depression with a decrease in the left ventricular EF by 
an echocardiogram after the IV phenobarbital load that returned to 
baseline prior to first maintenance dose of phenobarbital. There was 
no evidence that these measured changes were dependent on the 
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phenobarbital dose or serum level, since all children had similar 
loading doses and their serum levels did not correlate with their EF. 
There could have been a decrease in blood pressure and myocardial 
function in these children over time especially if there were ongoing 
seizures or other systemic insults such as trauma, hypoxia, and cardio-
pulmonary arrest. However, since our timed echocardiogram studies 
before and after loading of phenobarbital were obtained prospec-
tively, this was less likely. Moreover, previous adult human studies 
were in agreement with our findings. An adult study using IV infusion 
of phenobarbital for refractory seizures demonstrated hypotension 
requiring fluid resuscitation and vasopressors was seen in 32% of the 
cases.16 Another study in adults, a randomized trial using IV Thio-
pentone 5 mg/kg in patients with coronary artery disease and left 
ventricular dysfunction showed a similar hemodynamic response in 
comparison to three other anesthetic agents that were evaluated, with 
a 30% - 40% decrease in cardiac index.17  
Although this pilot study provides useful information for clinicians, 
a small sample size in this prospective single center pilot study was the 
most significant limitation. A larger multicenter study is recommend-
ed to confirm the findings and evaluate other clinical confounders that 
were not evaluated in this study. Due to the prospective and time-
based nature of the study, other sophisticated echocardiographic 
parameters of systolic and diastolic function were not obtained, 
such as myocardial performance index, strain imaging, 3D imaging, 
and tissue Doppler imaging to evaluate myocardium in more detail. 
Hence, further studies with a larger sample size looking at extensive 
systolic and diastolic function and physiology of peripheral vascula-
ture are warranted.
CONCLUSIONS
This pilot study in children showed that IV phenobarbital had a 
direct depressant effect on contractility of the left ventricular myo-
cardium. The decrease in left ventricular EF appeared to be transient 
with return to baseline in less than 24 hours. There was an accom-
panying transient decrease in systolic blood pressure in 30% of 
the children. We recommend close monitoring with anticipation of 
decreased function in children when using IV phenobarbital.
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